GSE192629
Vitamin C promotes anti-leukemia of DZNep in Acute Myeloid Leukemia
The epigenetic treatment by 3-Deazaneplanocin A (DZNep), a histone methyltransferase inhibitor, shows great potential against acute myeloid leukemia (AML). However, the variant sensitivity and incomplete response to DZNep are commonly observed. We reveal that vitamin C (Vc) dramatically promotes DZNep response against leukemic cells in different cell lines and primary AML samples. To examine the  molecular determinants underlying Vc enhanced anti-leukemia effect of DZNep, we conducted a genome-wide RNA sequencing and a gene ontology (GO) enrichment analysis of differentially expressed mRNAs in each group was performed. Overall design: The experiment was divided into four groups: PBS treatment group, VC treatment group, DZNep treatment group, VC and DZNep treatment group.